Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report

COVID-19, the illness caused by SARS-CoV-2, continues to cause significant morbidity and mortality across the world. An important step in overcoming SARS-CoV-2 is the global vaccination plan. Cases of acquired thrombotic thrombocytopenic purpura (aTTP) have been recently described after SARS-CoV-2 v...

Full description

Saved in:
Bibliographic Details
Main Authors: Domenica Caramazza, Marco Salvini, Vincenzo Saturni, Francesco Ripamonti, Michele Merli, Benedetta Bianchi, Stefania Agnoli, Davide Sirocchi, Barbara Mora, Elena Galfrascoli, Francesco Passamonti
Format: Article
Language:English
Published: American College of Physicians 2022-07-01
Series:Annals of Internal Medicine: Clinical Cases
Online Access:https://www.acpjournals.org/doi/10.7326/aimcc.2021.0110
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850198016759169024
author Domenica Caramazza
Marco Salvini
Vincenzo Saturni
Francesco Ripamonti
Michele Merli
Benedetta Bianchi
Stefania Agnoli
Davide Sirocchi
Barbara Mora
Elena Galfrascoli
Francesco Passamonti
author_facet Domenica Caramazza
Marco Salvini
Vincenzo Saturni
Francesco Ripamonti
Michele Merli
Benedetta Bianchi
Stefania Agnoli
Davide Sirocchi
Barbara Mora
Elena Galfrascoli
Francesco Passamonti
author_sort Domenica Caramazza
collection DOAJ
description COVID-19, the illness caused by SARS-CoV-2, continues to cause significant morbidity and mortality across the world. An important step in overcoming SARS-CoV-2 is the global vaccination plan. Cases of acquired thrombotic thrombocytopenic purpura (aTTP) have been recently described after SARS-CoV-2 vaccination. We describe a patient case of aTTP occurring 25 days after ChAdOx1 nCov-19 (Vaxzervria/AstraZeneca) vaccination that was promptly treated with plasma exchange, corticosteroids, rituximab, and caplacizumab. Remission of aTTP was achieved in 2 weeks and the patient is currently in complete remission.
format Article
id doaj-art-d2489e4a14f54024b8581f7db6fff69f
institution OA Journals
issn 2767-7664
language English
publishDate 2022-07-01
publisher American College of Physicians
record_format Article
series Annals of Internal Medicine: Clinical Cases
spelling doaj-art-d2489e4a14f54024b8581f7db6fff69f2025-08-20T02:12:58ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642022-07-011510.7326/aimcc.2021.0110Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case ReportDomenica Caramazza0Marco Salvini1Vincenzo Saturni2Francesco Ripamonti3Michele Merli4Benedetta Bianchi5Stefania Agnoli6Davide Sirocchi7Barbara Mora8Elena Galfrascoli9Francesco Passamonti101Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy2Transfusion Service, University Hospital Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy3Hospital Pharmacy, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy1Hematology, University Hospital ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, ItalyCOVID-19, the illness caused by SARS-CoV-2, continues to cause significant morbidity and mortality across the world. An important step in overcoming SARS-CoV-2 is the global vaccination plan. Cases of acquired thrombotic thrombocytopenic purpura (aTTP) have been recently described after SARS-CoV-2 vaccination. We describe a patient case of aTTP occurring 25 days after ChAdOx1 nCov-19 (Vaxzervria/AstraZeneca) vaccination that was promptly treated with plasma exchange, corticosteroids, rituximab, and caplacizumab. Remission of aTTP was achieved in 2 weeks and the patient is currently in complete remission.https://www.acpjournals.org/doi/10.7326/aimcc.2021.0110
spellingShingle Domenica Caramazza
Marco Salvini
Vincenzo Saturni
Francesco Ripamonti
Michele Merli
Benedetta Bianchi
Stefania Agnoli
Davide Sirocchi
Barbara Mora
Elena Galfrascoli
Francesco Passamonti
Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
Annals of Internal Medicine: Clinical Cases
title Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
title_full Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
title_fullStr Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
title_full_unstemmed Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
title_short Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report
title_sort acquired thrombotic thrombocytopenic purpura after chadox1 ncov 19 vaccine a case report
url https://www.acpjournals.org/doi/10.7326/aimcc.2021.0110
work_keys_str_mv AT domenicacaramazza acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT marcosalvini acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT vincenzosaturni acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT francescoripamonti acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT michelemerli acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT benedettabianchi acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT stefaniaagnoli acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT davidesirocchi acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT barbaramora acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT elenagalfrascoli acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport
AT francescopassamonti acquiredthromboticthrombocytopenicpurpuraafterchadox1ncov19vaccineacasereport